Likewise, the application of TNFR2 inhibition was tested in the pancreatic ductal adenocarcinoma (PDAC) and colon cancer mouse models using anti-PDL-1 and anti-PD-1 antibodies, respectively, and the findings were consistent with previous reports [175, 315]. This evidence concerns the gene TNFRSF1B and malignant colon neoplasm.